Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC review panel for botanical products should be FDA priority, commission advises.

This article was originally published in The Tan Sheet

Executive Summary

OTC REVIEW PANEL FOR BOTANICALS SUGGESTED AS FDA PRIORITY by the Commission on Dietary Supplement Labels in a draft report on supplement labeling claims and statements released June 24. "The commission strongly recommends that FDA put a priority on establishing an OTC review panel for botanical products that are intended for therapeutic and preventive use, with appropriate representation of experts on such products, at the earliest possible time," and that "FDA move forward promptly with such a review," the draft report declares. The panel should include experts with a background in pharmacognosy as well as other disciplines, the commission advises.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel